CD4+CD73+ T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression

AIDS

Volumn 27, Issue 10, 2013, Pages 1545-1555

  Schuler, Patrick J ^a,b   Macatangay, Bernard J C ^c   Saze, Zenichiro ^a   Jackson, Edwin K ^c   Riddler, Sharon A ^c   Buchanan, William G ^d   Hilldorfer, Benedict B ^c   Mellors, John W ^c   Whiteside, Theresa L ^a   Rinaldo, Charles R ^d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; C REACTIVE PROTEIN; CD39 ANTIGEN; CYCLIC AMP; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROLYSIS; IN VITRO STUDY; INCUBATION TIME; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION;

5'-NUCLEOTIDASE; ADENOSINE; ADULT; AGED; ANTIGENS, CD; APYRASE; BIOLOGICAL ASSAY; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MASS SPECTROMETRY; MIDDLE AGED;

EID: 84879124970     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328360c7f3     Document Type: Article

References (39)

1. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, et al. Aging and infectious diseases: workshop on HIV infection and aging - what is known and future research directions. Clin Infect Dis 2008; 47:542-553.
2. van Sighem A, Danner S, Ghani AC, Gras L, Anderson RM, de Wolf F. Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-infected individuals. J Acquir Immune Defic Syndr 2005; 40:212-218.
3. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.
4. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
5. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1881-1888.
6. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011; 203:452-463.
7. Smits HA, Boven LA, Pereira CF, Verhoef J, Nottet HS. Role of macrophage activation in the pathogenesis of Alzheimer's disease and human immunodeficiency virus type 1-associated dementia. Eur J Clin Invest 2000; 30:526-535.
8. Gibellini D, De Crignis E, Ponti C, Cimatti L, Borderi M, Tschon M, et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol 2008; 80:1507-1514.
9. Grund B, Neuhaus J, Phillips A. Relative risk of death in the SMART study. Lancet Infect Dis 2009; 9:724-725.
10. Piconi S, Parisotto S, Rizzardini G, Passerini S, Terzi R, Argenteri B, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011; 118:3263-3272.
11. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-870.
12. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8R T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4R cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:83-92.
13. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, et al. Endocytosis of HIV-1 activates plasmacy-toid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005; 115:3265-3275.
14. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.
15. Douek D. HIV disease progression: immune activation, microbes, and a leaky gut. Top HIV Med 2007; 15:114-117.
16. Brenchley JM, Douek DC. The mucosal barrier and immune activation in HIV pathogenesis. Curr Opin HIV AIDS 2008; 3:356-361.
17. Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, et al. Immune activation and CD8R T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2004; 2:E20.
18. Catalfamo M, Wilhelm C, Tcheung L, Proschan M, Friesen T, Park JH, et al. CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7. J Immunol 2011; 186:2106-2116.
19. Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, Kok A, et al. CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog 2011; 7:e1002110.
20. Moreno-Fernandez ME, Rueda CM, Rusie LK, Chougnet CA. Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism. Blood 2011; 117: 5372-5380.
21. Schulze Zur Wiesch J, Thomssen A, Hartjen P, Toth I, Lehmann C, Meyer-Olson D, et al. Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3R T regulatory cells correlates with progressive disease. J Virol 2011; 85:1287-1297.
22. Kumar V, Sharma A. Adenosine: an endogenous modulator of innate immune system with therapeutic potential. Eur J Pharmacol 2009; 616:7-15.
23. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3R Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110:1225-1232.
24. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204:1257-1265.
25. Dwyer KM, Hanidziar D, Putheti P, Hill PA, Pommey S, McRae JL, et al. Expression of CD39 by human peripheral blood CD4R CD25R T cells denotes a regulatory memory phenotype. Am J Transplant 2010; 10:2410-2420.
26. Schuler PJ, Schilling B, Harasymczuk M, Hoffmann TK, Johnson J, Lang S, et al. Phenotypic and functional characteristics of CD4R CD39R FOXP3R and CD4R CD39R FOXP3neg T-cell subsets in cancer patients. Eur J Immunol 2012; 42:1876-1885.
27. Law JP, Hirschkorn DF, Owen RE, Biswas HH, Norris PJ, Lanteri MC. The importance of Foxp3 antibody and fixation/permeabilization buffer combinations in identifying CD4RCD25R Foxp3R regulatory T cells. Cytometry A 2009; 75:1040-1050.
28. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-4536.
29. Jackson EK, Ren J, Mi Z. Extracellular 2',3'-cAMP is a source of adenosine. J Biol Chem 2009; 284:33097-33106.
30. Schuler PJ, Harasymczuk M, Schilling B, Lang S, Whiteside TL. Separation of human CD4RCD39R T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods 2011; 369:59-68.
31. Burton CT, Westrop SJ, Eccles-James I, Boasso A, Nelson MR, Bower M, et al. Altered phenotype of regulatory T cells associated with lack of human immunodeficiency virus (HIV)-1-specific suppressive function. Clin Exp Immunol 2011; 166:191-200.
32. Moreno-Fernandez ME, Presicce P, Chougnet CA. Homeostasis and function of regulatory T cells in HIV/SIV infection. J Virol 2012; 86:10262-10269.
33. Gutheil WG, Subramanyam M, Flentke GR, Sanford DG, Munoz E, Huber BT, et al. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. Proc Natl Acad Sci U S A 1994; 91:6594-6598.
34. Weihofen WA, Liu J, Reutter W, Saenger W, Fan H. Crystal structures of HIV-1 Tat-derived nonapeptides Tat-(1-9) and Trp2-Tat-(1-9) bound to the active site of dipeptidyl-peptidase IV (CD26). J Biol Chem 2005; 280:14911-14917.
35. Deaglio S, Robson SC. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv Pharmacol 2011; 61:301-332.
36. Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol 2012; 3:51.
37. Murray JL, Reuben JM, Munn CG, Mansell PW, Newell GR, Hersh EM. Decreased 5' nucleotidase activity in lymphocytes from asymptomatic sexually active homosexual men and patients with the acquired immune deficiency syndrome. Blood 1984; 64:1016-1021.
38. Buchheiser A, Ebner A, Burghoff S, Ding Z, Romio M, Viethen C, et al. Inactivation of CD73 promotes atherogenesis in apolipoprotein E-deficient mice. Cardiovasc Res 2011; 92:338-347.
39. Ho JE, Hsue PY. Cardiovascular manifestations of HIV infection. Heart 2009; 95:1193-1202.